Why These Weight Management Doses Aren't Directly Comparable
Understanding Mounjaro and Wegovy Equivalent Doses: The Key Differences
When searching for Mounjaro and Wegovy equivalent doses, it's crucial to understand that these prescription-only medicines don't have direct dose equivalents due to their fundamentally different mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist, while Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist. Both follow structured dose escalation protocols, but comparing their effectiveness isn't simply a matter of matching doses milligram-for-milligram. EverydayMeds offers both treatments through our GPhC-registered pharmacy (#9012878), allowing your prescriber to determine the most appropriate option based on your individual clinical profile and weight management goals.
The dosing schedules for both treatments prioritise safety through gradual escalation to minimise gastrointestinal side effects. Wegovy starts at 0.25mg weekly for four weeks, progressing to a maintenance dose of 2.4mg, while Mounjaro begins at 2.5mg weekly, escalating to maintenance doses of 10mg or 15mg. These aren't equivalent doses - they represent different therapeutic approaches to weight management. Your EverydayMeds prescriber will consider factors including your medical history, current medications, and treatment goals when recommending between these options.
Pricing and Value When Comparing Mounjaro and Wegovy Equivalent Doses
EverydayMeds offers transparent pricing for both Wegovy and Mounjaro, making it easier to understand the investment required for your chosen treatment. Wegovy pricing starts with the 0.25mg starter dose at £79.99 (after applying discount code FIRST40 for new customers), progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. Our bundled options provide convenience for managing your dose escalation, with the Intro Duo (0.25mg and 0.5mg) available for £169.99, covering your first eight weeks of treatment.
While Mounjaro and Wegovy equivalent doses can't be directly compared in terms of strength, both treatments require similar financial commitment over time due to their chronic nature. The value extends beyond the medication cost to include our comprehensive service: three-minute clinical assessment, expert prescriber review, genuine manufacturer medications, and next-day cold-chain delivery. Returning customers benefit from discount code DOSE25 at checkout, ensuring ongoing value throughout their weight management journey with either treatment option.
Clinical Evidence Supporting Mounjaro and Wegovy Equivalent Doses Approach
The clinical evidence for both treatments demonstrates the importance of proper dose escalation rather than seeking equivalent doses between different mechanisms. In the STEP trials, patients taking Wegovy alongside diet and exercise achieved an average weight loss of approximately 15% at 68 weeks (Wilding et al., NEJM, 2021). The structured dose escalation from 0.25mg to 2.4mg was crucial for both efficacy and tolerability in these studies.
Similarly, tirzepatide studies show the importance of gradual dose increases from 2.5mg to maintenance doses of 10mg or 15mg. Rather than focusing on Mounjaro and Wegovy equivalent doses, clinical evidence supports individualised treatment selection based on patient factors and response. Both treatments demonstrate cardiovascular benefits beyond weight loss, with the recent SELECT trial showing Wegovy may reduce major cardiovascular events by 20% in eligible patients.
How Wegovy Works: The GLP-1 Mechanism in Dose Comparison Context
Understanding how Wegovy works helps explain why Mounjaro and Wegovy equivalent doses aren't directly comparable. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural hormone GLP-1, which is released from the intestines after eating. This hormone signals the brain to promote feelings of fullness and reduce appetite, while also slowing gastric emptying to extend satiety after meals. The weekly injection delivers sustained semaglutide levels, providing consistent appetite regulation throughout the week. The dose escalation from 0.25mg to 2.4mg allows your body to gradually adapt to these metabolic changes while minimising potential side effects. This mechanism differs from Mounjaro's dual-action approach, explaining why simple dose equivalence isn't clinically meaningful.
Streamlined Ordering Process for Mounjaro and Wegovy Equivalent Doses
EverydayMeds has simplified the process of accessing both Wegovy and Mounjaro, removing the complexity of comparing equivalent doses by providing expert clinical guidance. Our three-minute online assessment captures your medical history, current medications, weight management goals, and any previous experience with GLP-1 treatments. Your completed assessment is reviewed by our qualified prescribers within three working days (or 24 hours with express service), who will recommend the most appropriate treatment and starting dose based on clinical guidelines. Once approved, your medication is dispatched via next-day delivery using temperature-controlled packaging to maintain the cold-chain integrity essential for these biological medicines. This process ensures you receive the right treatment rather than focusing on potentially misleading dose equivalencies between different medications.
Storage and Practical Considerations for Mounjaro and Wegovy Equivalent Doses
Both Wegovy and Mounjaro require refrigeration at 2-8°C before first use, but there are practical differences that may influence your choice beyond dose considerations. Wegovy can be stored at room temperature (below 30°C) for up to six weeks once removed from the fridge, while Mounjaro can only be kept at room temperature for 21 days. This storage advantage makes Wegovy more convenient for travel or if you don't have reliable refrigeration access. Both medications use pre-filled injection pens (Wegovy's FlexTouch and Mounjaro's KwikPen), making self-administration straightforward once you're familiar with the technique. The dose escalation schedules require different pen strengths over time, so planning your supply is important regardless of which treatment you choose. Your EverydayMeds prescriber will provide detailed guidance on injection technique, storage requirements, and dose progression timing.
Why Direct Mounjaro and Wegovy Equivalent Doses Don't Exist
The pharmaceutical science behind these treatments explains why seeking direct Mounjaro and Wegovy equivalent doses is fundamentally flawed. Tirzepatide (Mounjaro) acts on both GIP and GLP-1 receptors, creating a dual incretin effect that influences multiple metabolic pathways simultaneously. Semaglutide (Wegovy) specifically targets GLP-1 receptors with high selectivity and potency. These different mechanisms mean that a 10mg Mounjaro dose doesn't correspond to any specific Wegovy dose in terms of biological effect.
Additionally, the molecular structures, binding affinities, and pharmacokinetic profiles differ significantly between these medications. Clinical trials for each treatment used distinct protocols, patient populations, and endpoints, making direct efficacy comparisons inappropriate. Your EverydayMeds prescriber focuses on patient-specific factors rather than dose equivalencies, considering your medical history, previous treatment responses, lifestyle factors, and treatment preferences to recommend the most suitable option for your weight management goals.
Expert Clinical Support Beyond Mounjaro and Wegovy Equivalent Doses
EverydayMeds provides comprehensive clinical support that goes beyond simple dose comparisons, helping you achieve optimal outcomes with either treatment. Our prescribers offer ongoing monitoring and dose adjustment guidance, recognising that individual responses vary significantly regardless of the starting dose. We provide detailed injection training materials, side effect management strategies, and lifestyle guidance to maximise your treatment benefits alongside the required reduced-calorie diet and increased physical activity. Regular follow-up assessments ensure your chosen treatment continues to meet your needs, with the flexibility to adjust doses or switch treatments if clinically appropriate. This personalised approach delivers better outcomes than focusing solely on theoretical dose equivalencies between different medications, supported by our GPhC #9012878 registration and commitment to pharmaceutical excellence.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
